This clinical trial is focused on studying the effects of certain medications in individuals who have undergone a kidney transplantation. The medications being studied include CellCept (which contains the active ingredient mycophenolate mofetil), Prograf (which contains tacrolimus), and Prednisolone. Additionally, the trial will examine the impact of a calcium supplement called Calcigran Forte, which contains colecalciferol (a form of vitamin D) and calcium.
The purpose of the study is to investigate how the calcium supplement affects the way the body processes the medications tacrolimus and mycophenolate mofetil in people who have had a kidney transplant. Participants in the study will continue their regular medication regimen, which includes taking Prograf, CellCept, and Prednisolone, while also taking the calcium supplement. The study will monitor how these medications are absorbed and processed in the body over a period of time.
Throughout the study, participants will be asked to take their medications as prescribed and may be required to provide samples for analysis. The study aims to provide valuable information on the interaction between the calcium supplement and the immunosuppressive drugs used by kidney transplant recipients. This information could help improve treatment plans and outcomes for individuals who have received a kidney transplant.
Norway 
